An 81-year-old man named William Shakespeare has become the second person in the world to receive the coronavirus vaccine outside of a trial.
Health authorities in the United Kingdom began rolling out the first doses of a widely tested and independently reviewed Covid-19 vaccine on Tuesday, starting a global immunisation programme that is expected to gain momentum as more serums win approval.
The first shot came early in the morning at one of a network of hospital hubs around the country where the initial phase of the UK programme will be rolled out on what has been dubbed “V-Day”.
Public health officials are asking the public to be patient because only those who are most at risk from Covid-19 will be vaccinated in the early stages. Medical staff will contact people to arrange appointments, and most will have to wait until next year before there is enough vaccine to expand the programme.
“I think there’s every chance that we will look back on … [Tuesday] as marking a decisive turning point in the battle against coronavirus,” said Sir Simon Stevens, the chief executive of the National Health Service.
* Covid-19: Donald Trump administration passed up chance to lock in more Pfizer vaccine doses
* Covid-19: UK readies for ‘V-Day,’ its first vaccine shots in the war on coronavirus
* UK gears up for huge vaccination plan watched by the world
* Covid-19: The beginning of the end of the coronavirus pandemic
The first recipient was grandmother Margaret Keenan, who turns 91 next week. She received the shot at University Hospital Coventry at 6:31am (local time).
Keenan says she felt “so privileged to be the first person vaccinated against Covid-19”.
“It’s the best early birthday present I could wish for because it means I can finally look forward to spending time with my family and friends in the new year after being on my own for most of the year,” she said.
Warwickshire local Shakespeare, who became the second recipient, said he was a bit apprehensive about potential side effects, but thought the possibility of them being bad would most likely be low.
The first 800,000 doses are going to people aged over 80 who are either hospitalised or already have outpatient appointments scheduled, along with nursing home workers. Others will have to wait their turn.
Among those older Britons scheduled to get vaccinated is Hari Shukla, of Newcastle.
“When I received the telephone call, I was very excited I got the opportunity of joining in and taking part in that,” he said. “So we are very, very pleased and happy and excited as well.”
Buckingham Palace refused to comment on reports that the Queen, 94, and her 99-year-old husband, Prince Philip, would be vaccinated as a public example of its safety.
“Our goal is totally to protect every member of the population, Her Majesty, of course, as well,” Dr June Raine, the chief executive of Britain’s Medicines and Healthcare products Regulatory Agency, told the BBC.
Public health officials elsewhere are watching Britain’s rollout as they prepare for the unprecedented task of vaccinating billions of people to end a pandemic that has killed more than 1.5 million. While the UK has a well-developed infrastructure for delivering vaccines, it is geared to administer them to groups such as school children or pregnant women, not the whole population.
The UK is getting a head start on the project after British regulators gave emergency authorisation on December 2, to the vaccine produced by US pharmaceutical company Pfizer and Germany’s BioNTech.
United States and European Union authorities are also reviewing the vaccine, alongside rival products developed by US biotechnology company Moderna, and a collaboration between Oxford University and pharmaceutical company AstraZeneca.
On Saturday, Russia began vaccinating thousands of doctors, teachers and others at dozens of centres in Moscow with its Sputnik V vaccine. That programme is being viewed differently because Russia authorised use of Sputnik V last summer after it was tested in only a few dozen people.
The first shipments of the Pfizer-BioNTech vaccine were delivered to a selected group of UK hospitals on Sunday.
At one of those facilities, Croydon University Hospital, south of London, staff members couldn’t so much as touch the vials, but they were thrilled to just have them in the building.
“I’m so proud,” said Louise Coughlan, a joint chief pharmacist at Croydon Health Services NHS Trust.
The vaccine can’t arrive soon enough for the UK, which has had more than 61,000 Covid-related deaths and more than 1.7 million cases.
The 800,000 doses are only a fraction of what is needed. The government is targeting more than 25 million people, or about 40 per cent of the population, in the first phase of its vaccination programme, which gives first priority to those who are at the highest risk from the disease.
After those over 80 and nursing home workers, the program will be expanded as the supply increases, with the vaccine offered roughly on the basis of age groups, starting with the oldest people.
In England, the vaccine will be delivered at 50 hospital hubs in the first wave of the programme, with more hospitals expected to offer it as the rollout ramps up. Northern Ireland, Scotland and Wales are making their own plans under the UK’s system of devolved administration.
Logistical issues are slowing the distribution of the Pfizer vaccine because it has to be stored at minus 70 degrees Celsius.
The immunisation programme will be a “marathon not a sprint”, said Professor Stephen Powis, the medical director for NHS England.
Authorities also are focusing on large-scale distribution points because each package of vaccine contains 975 doses and they don’t want any to be wasted.
The UK has agreed to buy millions of doses from seven different producers. Governments around the world are making agreements with multiple developers to ensure they lock in delivery of the products that are ultimately approved for widespread use.